---
id: burkholderia-pseudomallei-melioidosis_069
category: organisms
tags: [burkholderia-pseudomallei, melioidosis, ceftazidime, meropenem, TMP-SMX, endemic, sepsis]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Burkholderia pseudomallei (Melioidosis)

**Q:** What are the clinical presentations, endemic regions, and treatment approach (intensive + eradication phases) for melioidosis?

**A:**

**Microbiology:**
- **Gram-negative bacillus** (aerobic, motile)
- **Burkholderia pseudomallei** (formerly Pseudomonas pseudomallei)
- **Environmental:** Soil, stagnant water (endemic tropical areas)
- Facultative intracellular pathogen (survives in macrophages)
- **Biphasic treatment required** (acute → eradication)

**Intrinsic Resistance:**
- Aminoglycosides, polymyxins, early-generation cephalosporins
- **Naturally resistant** to many antibiotics (AmpC β-lactamase, efflux pumps)

---

**Epidemiology & Geography:**

**Endemic Areas:**
- **Southeast Asia:** Thailand (#1), Malaysia, Singapore, Vietnam, Laos, Cambodia
- **Northern Australia** (especially Northern Territory, Queensland)
- **South Asia:** India, Bangladesh, Sri Lanka
- Sporadic: Caribbean, Central/South America, Africa, Middle East

**US Cases:**
- Rare (travel-associated)
- **2021-2022:** Outbreak from aromatherapy spray (4 cases, 2 deaths)

**Transmission:**
- **Percutaneous inoculation** (skin wounds, abrasions) - most common
- **Inhalation** (dust, aerosolized soil/water)
- **Ingestion** (contaminated water)
- **Aspiration** (near-drowning)
- **NOT person-to-person**

---

**Risk Factors:**

**Major Risk Factors ("DDDER"):**
- **D**iabetes mellitus (#1 risk factor - 50% of cases)
- **D**rug use (alcohol abuse)
- **E**xposure (occupational - rice farmers, construction workers)
- **R**enal disease (chronic kidney disease)

**Other:**
- Thalassemia, chronic lung disease, immunosuppression

**Key Point:** 50% of melioidosis patients have **diabetes**

---

**Clinical Presentation:**

**Incubation:** 1-21 days (average 9 days), but can be years (latent infection → reactivation)

**Spectrum:** Asymptomatic → localized → disseminated sepsis

**Clinical Forms:**

**1. Acute Pulmonary Melioidosis (Most Common - 50%):**

**Presentation:**
- **Fever, cough, chest pain**
- **Productive sputum** (may be blood-tinged)
- **Dyspnea**
- Rapid progression (can mimic CAP or TB)

**Imaging:**
- **Upper lobe infiltrates** (mimics TB!)
- **Cavitation** (30-40%)
- **Pleural effusion**
- **Multiple nodules or consolidation**

**Key Clue:** "Mimics TB" but from endemic area

**2. Septicemic Melioidosis (30-40%):**

**Presentation:**
- **Acute sepsis/septic shock**
- **Multiorgan involvement:**
  - **Liver:** Abscess (40%)
  - **Spleen:** Abscess (30%)
  - **Lung:** Pneumonia
  - **Prostate:** Abscess (men)
  - **Kidney:** Abscess
- **DIC, ARDS**

**Mortality:** 40-50% (even with treatment)

**Imaging:**
- **"Swiss cheese" liver/spleen** (multiple abscesses)

**3. Localized Melioidosis:**

**Skin/Soft Tissue:**
- Ulcer, abscess, cellulitis at inoculation site
- Lymphadenopathy

**Osteoarticular:**
- Osteomyelitis, septic arthritis (rare)

**Other:**
- Parotid abscess (children)
- Prostate abscess (men - check!)
- Genital ulcers

**4. Chronic Melioidosis (10%):**

**Presentation:**
- **Indolent course (>2 months)**
- **Mimics TB** (chronic cough, weight loss, night sweats, cavitary lung disease)
- **Skin/soft tissue abscesses**

**5. Latent Melioidosis:**
- Asymptomatic infection → reactivation years later
- **"Vietnamese time bomb"** (soldiers reactivate decades after Vietnam War)

---

**Diagnosis:**

**Culture (Gold Standard):**
- **Blood, sputum, abscess fluid, urine**
- **Ashdown's agar** (selective medium)
- Growth: 24-48h (can take up to 7 days)
- **Alert lab:** Potential bioterrorism agent (CDC Category B)

**Microscopy:**
- **"Safety pin" bipolar staining** (Wright/Giemsa stain)

**Serology:**
- **IHA (indirect hemagglutination):** Titer ≥1:160 (endemic areas: background seropositivity)
- Not diagnostic (background seropositivity in endemic areas)

**PCR:**
- Rapid (16S rRNA, fliC, etc.)
- Available in reference labs

**Imaging:**
- **CT chest/abdomen:** Multiple abscesses ("Swiss cheese" liver/spleen)

---

**Treatment:**

**Principle:** **Biphasic therapy** (intensive → eradication)

**Why Biphasic?**
- **Acute phase:** Treat severe infection, prevent death
- **Eradication phase:** Eliminate intracellular bacteria, prevent relapse
- **Relapse rate without eradication:** 20-30%

---

**Phase 1: Intensive (Acute) Phase**

**Duration:** Minimum **10-14 days** (extend up to 8 weeks for severe/complicated cases)

**First-Line Antibiotics:**

| **Antibiotic** | **Dosing** | **Duration** | **Notes** |
|----------------|------------|--------------|-----------|
| **Ceftazidime** (preferred) | 2g (50 mg/kg) IV q6-8h | 10-14 days minimum | First-line |
| **Meropenem** | 1g (25 mg/kg) IV q8h | 10-14 days minimum | Alternative (severe cases, CNS) |
| **Imipenem** | 1g (20 mg/kg) IV q6-8h | 10-14 days minimum | Alternative |

**Adjunctive (Controversial):**
- **TMP-SMX:** 8 mg/kg/day (TMP component) IV divided q6-8h (some experts add during intensive phase)

**Rationale:**
- **Ceftazidime:** 100% susceptible, excellent activity
- **Meropenem:** Better for CNS disease, severe sepsis (some prefer over ceftazidime)
- **TMP-SMX adjunctive:** May reduce mortality (observational data, not proven in RCTs)

**Duration Extension:**
- **Severe sepsis:** 4 weeks
- **Deep-seated abscess:** 4-8 weeks
- **CNS involvement:** 6-8 weeks
- **Osteomyelitis:** 8 weeks

---

**Phase 2: Eradication (Oral) Phase**

**Duration:** **3-6 months** (minimum 3 months, extend to 6 months for complicated cases)

**First-Line:**

| **Regimen** | **Dosing** | **Duration** |
|-------------|------------|--------------|
| **TMP-SMX** (preferred) | 8-10 mg/kg/day (TMP component) PO divided BID (e.g., 2 DS tablets BID) | 3-6 months |
| **Amoxicillin-clavulanate** | 20 mg/kg PO TID (amoxicillin component) | 3-6 months |

**Notes:**
- **TMP-SMX preferred** (lower relapse rate: 10% vs 20% with amox-clav)
- **If TMP-SMX intolerant:** Use amoxicillin-clavulanate
- **Doxycycline:** Alternative (less effective, higher relapse)

**Duration:**
- **Uncomplicated:** 3 months
- **Complicated (abscess, osteomyelitis, CNS):** 6 months (or longer)

**Monitoring:**
- Clinical response
- Repeat imaging (abscesses)
- **Relapse risk:** 5-10% (higher if eradication <3 months)

---

**Special Considerations:**

**CNS Melioidosis (Brainstem encephalitis, abscess):**
- **Meropenem preferred** (better CSF penetration than ceftazidime)
- Intensive phase: 6-8 weeks
- Eradication phase: 6 months

**Pregnancy:**
- **Ceftazidime safe** (acute phase)
- **Avoid TMP-SMX** (eradication phase) → use amoxicillin-clavulanate

**Prostate Abscess:**
- Common in men
- **Screen with rectal exam, TRUS**
- Drainage may be needed
- Prolonged eradication (6 months)

**Children:**
- Same regimens (weight-based dosing)

---

**Prognosis:**

**Mortality:**
- **Septicemic melioidosis:** 40-50%
- **Pulmonary melioidosis:** 10-20%
- **Localized:** <5%

**Predictors of Mortality:**
- Septic shock
- Bacteremia
- Delayed treatment (>48h)
- Diabetes
- Renal failure
- CNS involvement

**Relapse:**
- 5-10% (with adequate eradication therapy)
- 20-30% (if eradication <3 months or inadequate)

---

**Post-Exposure Prophylaxis:**

**Indications:**
- Laboratory exposure
- Near-drowning in endemic area

**Regimen:**
- **TMP-SMX** 160/800 mg PO BID x 21 days

---

**Comparison: B. pseudomallei vs B. cepacia Complex**

| **Feature** | **B. pseudomallei** | **B. cepacia Complex** |
|-------------|---------------------|------------------------|
| **Geography** | **Endemic (SE Asia, Australia)** | Worldwide |
| **Primary risk** | **Diabetes** (50%) | **Cystic fibrosis** |
| **Transmission** | **Environmental** (soil, water) | Nosocomial, person-to-person (CF) |
| **Clinical** | Sepsis, abscesses ("Swiss cheese") | CF exacerbation, Cepacia syndrome |
| **Treatment** | **Biphasic:** Ceftazidime/meropenem → TMP-SMX | TMP-SMX, ceftazidime, meropenem (combination) |
| **Duration** | **3-6 months** (eradication) | 14-21 days |
| **Mortality** | 40-50% (septicemic) | >50% (Cepacia syndrome) |

---

**Mnemonic: "MELIOIDOSIS = Mimics TB, Endemic tropics, Lives in soil, Intensive phase (ceftazidime), Oral eradication (TMP-SMX), Diabetes, Sepsis, Swiss cheese abscesses"**
- **M**imics TB (cavitary lung)
- **E**ndemic (SE Asia, Australia)
- **L**ives in soil/water
- **I**ntensive phase (ceftazidime/meropenem)
- **O**ral eradication (TMP-SMX 3-6 months)
- **D**iabetes (#1 risk)
- **S**epsis (high mortality)
- **I**ntensive + eradication = **S**uccess

**Mnemonic: "Biphasic = IV then PO"**
- **I**V ceftazidime (2 weeks minimum)
- **P**O TMP-SMX (3-6 months)

**Clinical Pearls:**
- **Melioidosis = "great mimicker"** (can look like TB, pneumonia, abscess, sepsis)
- **Endemic areas:** SE Asia (#1 Thailand), Northern Australia
- **Diabetes = #1 risk factor** (50% of cases)
- **Biphasic treatment essential:** Ceftazidime/meropenem (intensive) → TMP-SMX (eradication)
- **Minimum eradication: 3 months** (relapse risk 20-30% if <3 months)
- **Swiss cheese liver/spleen** (multiple abscesses) on imaging
- **Cavitary lung disease** (mimics TB!)
- **Prostate abscess common in men** (screen with rectal exam)
- **NOT person-to-person** (unlike B. cepacia in CF)
- **Latent infection possible** ("Vietnamese time bomb" - reactivation years later)
- 100% susceptible to ceftazidime and meropenem
- **CNS disease:** Use meropenem (better CSF penetration), 6-8 weeks intensive + 6 months eradication

**Media:** None

**Sources:** [CDC Yellow Book 2024 - Melioidosis], [CDC 2024 - Melioidosis clinical overview], [MDPI 2023 - Effective therapeutic options], [PMC 2024 - Evaluation standardized treatment regimens Thailand], [PMC 2014 - Treatment and prophylaxis], [PMC 2013 - Mechanisms antibiotic resistance], [Merck Manual 2024 - Melioidosis], [CDC EID 2012 - Workshop on treatment and PEP]
